Enterprise value to revenue forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA
This article provides a specific financial metric, "Enterprise value to revenue forward," for Olema Pharmaceuticals, Inc. (NASDAQ: OLMA). It indicates that the value for this metric is currently unavailable or not specified, only noting the period, value, change, and percentage change. The content highlights the stock's listing on the Nasdaq Stock Market.
Price to sales forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA
This article provides financial information for Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), focusing on its forward price to sales metric. It highlights that the data for this financial indicator is contributed by human analysis, suggesting a qualitative aspect to the valuation. The article, originating from TradingView, lists several financial data providers, emphasizing market data for this pharmaceutical company.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) announced that it granted stock options to eight new employees to purchase 215,800 shares of common stock, effective July 1, 2026. These inducement grants were made under the Company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have a 10-year term, an exercise price of $12.08 per share, and vest over four years.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. announced that it granted stock options to eight new employees to purchase an aggregate of 215,800 shares of its common stock, effective July 1, 2026. These inducement grants were made under the Company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have a four-year vesting schedule, a 10-year term, and an exercise price of $12.08 per share.
Is Olema Pharmaceuticals (OLMA) A Bargain After Its Russell Index Additions?
Olema Pharmaceuticals (OLMA) has been added to several Russell growth benchmarks, increasing its visibility to institutional investors. Despite a recent mix of share price volatility, the company's valuation, based on a discounted cash flow model, suggests it is significantly undervalued, with an estimated future cash flow value of $212.47 per share against a current price of $12.64. However, the article highlights key risks including clinical trial setbacks and the need for funding as the company currently reports no revenue.
Olema Oncology awards 215,800 options to eight new employees
Olema Oncology (Nasdaq: OLMA) announced it granted stock options to eight new employees to purchase an aggregate of 215,800 shares of common stock, effective July 1, 2026. These inducement awards were made under its 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a 10-year term, an exercise price of $12.08 per share, and vest over four years, contingent on continued employment.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) announced inducement grants of stock options to eight new employees. These options, totaling 215,800 shares, vest over four years and were granted under the Company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price is $12.08 per share, based on the stock's closing price on July 1, 2026.
Olema Pharmaceuticals (OLMA) Is Up 22.0% After Broad Russell Growth Index Inclusion - Has The Bull Case Changed?
Olema Pharmaceuticals (OLMA) has seen a 22% stock increase following its inclusion in multiple Russell Growth Benchmarks, including the Russell 2000, 2500, and 3000 indices. While this inclusion boosts visibility and trading liquidity, the company's investment narrative remains fundamentally tied to the success of its high-risk oncology pipeline and upcoming clinical trial readouts, rather than the index changes. Despite potential undervaluation noted by some analysts, Olema's zero revenue and significant annual losses indicate that the index inclusion doesn't reduce its inherent financing and trial-execution risks.
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to Russell Small Cap Comp Growth Benchmark
Olema Pharmaceuticals, Inc. (NasdaqGS:OLMA) has been added to the Russell Small Cap Comp Growth Benchmark. This news comes amidst other recent developments for the company, including presentations at healthcare conferences and clinical trial collaborations for its experimental cancer treatments. The article also provides an overview of the company's profile, financial data, and analyst consensus.
Olema Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:OLMA)
This article provides an overview of Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) stock, including its current price, historical performance, and analyst forecasts. It details financial actuals and estimates, key financial metrics, and company information. The article also answers frequently asked questions about OLMA stock.
OLMA Forecast — Price Target — Prediction for 2027
Olema Pharmaceuticals, Inc. (OLMA) has a current stock price of $11.43, with analysts providing a 1-year price forecast ranging from $23.00 to $62.00, and a consensus target of $40.70. The company's stock has seen significant volatility, with a 143.71% increase over the last year but a monthly fall of -16.96%. OLMA is projected to release its next earnings report on August 11, 2026.
Olema (NASDAQ: OLMA) director receives grant of 29,500 stock options at $9.51
Olema Pharmaceuticals director Harmon Cyrus was granted 29,500 stock options with an exercise price of $9.51 per share, expiring on June 18, 2036. The options vest in 12 equal monthly installments beginning June 18, 2026, contingent on continued service, or fully vest at the next annual meeting if not already vested. This transaction is considered a compensation-related derivative acquisition, not a market purchase or sale of shares.
Olema (OLMA) director Graham Walmsley awarded 29,500 stock options at $9.51
Olema Pharmaceuticals director Graham G. Walmsley was granted 29,500 stock options with an exercise price of $9.51 per share, expiring on June 18, 2036. The options will vest in 12 equal monthly installments beginning June 18, 2026, or fully on the date of Olema's next annual stockholder meeting, contingent on his continued service. Following this grant, Walmsley directly holds 29,500 stock options.
Olema Pharmaceuticals (NASDAQ: OLMA) investors approve board slate, pay plan and Ernst & Young
Olema Pharmaceuticals (NASDAQ: OLMA) stockholders approved the election of four Class III directors, an advisory executive compensation program, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the 2026 fiscal year at their annual meeting on June 17, 2026. Sean Bohen, Scott Garland, Yi Larson, and Andrew Rappaport were elected as directors to serve until the 2029 annual meeting. The executive compensation received significant support, as did the choice of auditor.
Olema Pharmaceuticals (OLMA) director awarded 29,500 stock options at $9.51 strike price
Olema Pharmaceuticals director Cynthia M. Butitta was granted 29,500 stock options at an exercise price of $9.51 per share. These options serve as compensation and will vest in 12 equal monthly installments starting June 18, 2026, provided she continues her service. Any unvested portions will fully vest by the date of Olema's next annual meeting of stockholders if not already fully vested.
Olema (OLMA) director receives 29,500 options at $9.51 strike price
Olema Pharmaceuticals director Sandra Horning was granted 29,500 stock options with an exercise price of $9.51 per share, expiring on June 18, 2036. The options will vest in 12 equal monthly installments starting June 18, 2026, contingent on her continuous service, with any unvested portion fully vesting at the company's next annual stockholder meeting. This transaction is considered a neutral filing impact by Rhea-AI, representing routine equity-based compensation rather than an open-market purchase or sale.
Olema (NASDAQ: OLMA) director granted 29,500 stock options at $9.51 strike price
Olema Pharmaceuticals director Andrew Rappaport was granted 29,500 stock options at an exercise price of $9.51 per share, as part of his compensation. These options, which expire on June 18, 2036, vest in 12 equal monthly installments starting June 18, 2026, or fully on the next annual stockholder meeting date, provided he maintains continuous service to the company. This Form 4 filing reports a grant, not a sale or purchase of shares.
Olema (OLMA) director Garland J. Scott awarded 29,500 stock options at $9.51
Olema Pharmaceuticals director Garland J. Scott was granted 29,500 stock options with an exercise price of $9.51 per share, expiring on June 18, 2036. These options vest in 12 equal monthly installments starting June 18, 2026, contingent on Scott's continuous service. This grant brings his direct holdings of options to 29,500 shares, with full vesting also occurring at the next annual stockholder meeting if not already fully vested.
Form 4 Olema Pharmaceuticals Inc For: 23 June By Investing.com
This article from Investing.com reports that a Form 4 filing for Olema Pharmaceuticals Inc. was released on June 23rd. The brief piece includes the stock symbol OLMA and notes a 5.79% increase. It also features a general Reuters image.
Form 4 Olema Pharmaceuticals Inc For: 23 June By Investing.com
This article announces the filing of Form 4 for Olema Pharmaceuticals Inc. on June 23. It notes that the company's stock, OLMA, showed a 5.79% increase and includes various financial market data and related news. The content is primarily a brief announcement paired with general market information and trends.
Olema Pharmaceuticals (OLMA) director granted 29,500 stock options at $9.51 strike
Olema Pharmaceuticals director Ian T. Clark was granted 29,500 stock options with an exercise price of $9.51 per share, expiring on June 18, 2036. The options will vest in 12 equal monthly installments starting June 18, 2026, or earlier if the company's next annual stockholder meeting occurs sooner, contingent on his continued service. This transaction was reported via a Form 4 SEC filing, indicating a compensation award rather than an open-market purchase or sale.
Olema (NASDAQ: OLMA) awards director 29,500 stock options
Olema Pharmaceuticals director Gorjan Hrustanovic received a grant of 29,500 stock options with an exercise price of $9.51 per share, expiring in 2036. The options vest in monthly installments over 12 months, with full vesting contingent on continued service and potentially accelerating at the next annual stockholder meeting. Hrustanovic disclaims beneficial ownership, as any economic benefit from the sale of shares upon exercise is payable to BVF Partners L.P.
[Form 4] Olema Pharmaceuticals, Inc. Insider Trading Activity
Olema Pharmaceuticals director Yi Larson has received a grant of stock options for 29,500 shares of Common Stock, with an exercise price of $9.51 per share and an expiration date of June 18, 2036. The options vest in 12 equal monthly installments from June 18, 2026, subject to continued service, or will fully vest earlier if Olema’s next annual meeting occurs and service continues. This transaction, a grant/award of stock options, is categorized as neutral in impact and sentiment by Rhea-AI.
Olema Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans - moomoo
This document is an S-8 filing by Olema Pharmaceuticals, serving as an initial registration statement. It pertains to securities that the company plans to offer to its employees through various employee benefit plans. The filing indicates the formal registration process for these equity offerings.
Olema Pharmaceuticals Inc (OLMA) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a detailed risk assessment for Olema Pharmaceuticals Inc (OLMA), focusing on volatility, financial risk, and investment risk. It presents various financial metrics including beta, VaR, maximum drawdown, volatility over different periods, Sharpe Ratio, and liquidity indicators. The data aims to help investors understand the inherent risks associated with OLMA stock.
Olema Pharmaceuticals Inc (OLMA) Financial Health: Profitability & Balance Sheet Analysis
This TradingKey analysis of Olema Pharmaceuticals Inc (OLMA) focuses on its financial health, examining profitability and balance sheet data. The article, however, notes that relevant data for key financial metrics such as cash and cash equivalents, total assets, total revenue, and operating profit have not yet been disclosed by the company. It briefly touches upon the stock's performance and market capitalization.
Olema Pharmaceuticals Inc (OLMA) Institutional Confidence
This article from TradingKey provides an overview of institutional confidence in Olema Pharmaceuticals Inc (OLMA). It lists several major institutional shareholders, including Paradigm BioCapital Advisors LP, Janus Henderson Investors, and Fidelity Management & Research Company LLC, along with their shareholdings and percentage changes. The information highlights significant increases in holdings by some institutions, reflecting their confidence in the company.
Olema Pharmaceuticals Inc (OLMA) Dividends & Stock Splits: Historical Payouts and Event Timeline
The article provides an overview of Olema Pharmaceuticals Inc (OLMA) focusing on its dividend and stock split history. It states that OLMA has not distributed any dividends over the past five years and has no recorded stock split events. The page also includes current stock price information and market capitalization for Olema Pharmaceuticals.
Olema Pharmaceuticals Inc (OLMA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Olema Pharmaceuticals Inc (OLMA), detailing its business segments, regional revenue, and profit contribution. The report indicates that relevant financial data for these categories have not yet been disclosed by the company. The article also provides stock performance data, market capitalization, and links to other financial analysis tools.
Olema Pharmaceuticals Inc (OLMA) Shareholder Structure: Major Shareholders & Institutional Holdings
The article details the shareholder structure of Olema Pharmaceuticals Inc (OLMA), listing major individual and institutional holders and their respective proportions. It also outlines the types of shareholders, such as investment advisors, hedge funds, and venture capital, and provides a historical overview of institutional shareholding changes over recent quarters. Additionally, the article lists related ETFs that include OLMA in their portfolios.
10 Small Cap Stocks with Potential to Rise 1000 Percent
This article highlights small-cap stocks with significant growth potential, focusing on Olema Pharmaceuticals, Inc. (NASDAQ:OLMA). Olema recently reported positive initial Phase 1 clinical data for its KAT6 inhibitor, OP-3136, showing anti-tumor activity and good tolerability. The company anticipates topline data from its Phase 3 OPERA-01 trial for palazestrant in fall 2026 and continues enrollment for its OPERA-02 trial, backed by a strong cash position.
OLMA Stock Soars 47% in September So Far on Second PFE Deal
The article reports that OLMA stock has risen significantly in September due to its second deal with Pfizer (PFE). This suggests that the market is responding positively to OLMA's strategic partnerships and potential future growth.
OLMA,GH Options
This article provides detailed financial and performance data for two companies: Olema Pharmaceuticals Inc. (OLMA) and Guardant Health Inc. (GH). For OLMA, it lists a closing price of $9.82 with a 6.03% decrease, noting its market cap, insider ownership, and various performance metrics. For GH, it shows a closing price of $130.70 with a 0.45% increase, detailing its much larger market cap, institutional ownership, and strong year-to-date and yearly performance.
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating
J.P. Morgan has reiterated its Buy rating on Olema Pharmaceuticals (OLMA.US). The article does not provide specific details from the analyst report, such as a price target or the reasons behind the maintained rating.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology announced that it granted stock options to six new employees to purchase an aggregate of 176,150 shares of the Company's common stock, effective June 1, 2026. These inducement grants were made under the Company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options vest over four years with a 10-year term and an exercise price of $12.71 per share.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology announced that it granted stock options to six new employees to purchase an aggregate of 176,150 shares of the Company's common stock. These grants were made under the Company's 2022 Inducement Plan as an inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options vest over four years, have a 10-year term, and an exercise price of $12.71 per share.
A Look At Olema Pharmaceuticals (OLMA) Valuation After New Bayer Collaboration And OP-3136 Phase 1 Data
Olema Pharmaceuticals' valuation is under scrutiny after a new collaboration with Bayer and positive Phase 1 data for OP-3136. Despite a recent share price decline of 25% over 30 days and 56% over 90 days, the stock shows a strong 1-year total return. The company appears undervalued with a P/B ratio of 1.9x and a DCF fair value of $181.73 per share, significantly above its current trading price of $10.69, though sensitivity to clinical success and profitability assumptions is noted for this early-stage biotech.
A Look At Olema Pharmaceuticals (OLMA) Valuation After New Bayer Collaboration And OP-3136 Phase 1 Data
Olema Pharmaceuticals (OLMA) is being re-evaluated after a new collaboration with Bayer and positive Phase 1 data for its drug OP-3136. Despite short-term stock price declines (25% in 30 days, 56% in 90 days), the company's P/B ratio of 1.9x suggests it's undervalued compared to its peers (3.7x) and the broader biotech industry (2.6x). A discounted cash flow (DCF) model further indicates significant undervaluation, estimating a fair value of $181.73 per share against a current price of $10.69, though this relies on future assumptions for a clinical-stage, loss-making company.
Why Olema Pharmaceuticals (OLMA) Is Down 7.1% After Bayer OP-3136 Prostate Cancer Trial Deal And Data
Olema Pharmaceuticals (OLMA) saw its stock drop 7.1% despite announcing promising preliminary Phase 1 data for its KAT6 inhibitor OP-3136 and a clinical trial collaboration with Bayer for prostate cancer. While the Bayer deal adds external validation and a second major partner, it doesn't fundamentally change Olema's high-risk investment profile, which is centered on its ER+/HER2- breast cancer drug palazestrant and early-stage epigenetic play OP-3136, with the company currently having zero revenue and rising losses. The stock's performance this year indicates that near-term catalysts are tied to clinical milestones and balance sheet visibility rather than earnings.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) announced inducement grants to six new employees, consisting of stock options to purchase 176,150 shares of common stock. These grants were effective June 1, 2026, and were made under the company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have a 10-year term and an exercise price of $12.71 per share, vesting over four years.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology announced it granted stock options to six new employees to purchase 176,150 shares of common stock, effective June 1, 2026. These inducement grants were approved by the Compensation Committee under the Company's 2022 Inducement Plan, adhering to Nasdaq Listing Rule 5635(c)(4). The stock options vest over four years, have a 10-year term, and an exercise price of $12.71 per share.
Why Olema Pharmaceuticals (OLMA) Is Down 7.1% After Bayer OP-3136 Prostate Cancer Trial Deal And Data
Olema Pharmaceuticals experienced a 7.1% stock drop despite announcing positive preliminary Phase 1 data for its KAT6 inhibitor OP-3136 and a clinical trial collaboration with Bayer for prostate cancer. While the Bayer deal provides external validation and allows Olema to retain commercial rights, the company still faces significant risks, including zero revenue, rising losses, dependence on clinical trial success, and potential future dilution. The collaboration, involving a small Phase 1b/2 trial, strengthens the investment story but does not fundamentally alter the high-risk profile of Olema Pharmaceuticals.
Olema Pharmaceuticals, Bayer Collaborate to Test Potential Prostate Cancer Combination Therapy
Olema Pharmaceuticals and Bayer are collaborating to test a potential combination therapy for prostate cancer. The article also briefly mentions Unity Software's fourth-quarter financial results, reporting increased revenue and a quarterly loss.
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
Olema Oncology has announced a clinical trial collaboration and supply agreement with Bayer to evaluate OP-3136, Olema’s novel KAT6 inhibitor, in combination with Bayer’s NUBEQA® (darolutamide) for metastatic castration-resistant prostate cancer (mCRPC). The Phase 1b/2 study will assess the safety, tolerability, and preliminary anti-tumor activity in approximately 36 mCRPC patients, with initiation expected in the second half of 2026. This collaboration marks the first clinical partnership for OP-3136 and aims to inform future combination strategies for metastatic prostate cancer.
New prostate cancer trial pairs Olema drug with Bayer’s NUBEQA
Olema Oncology announced a clinical trial collaboration and supply agreement with Bayer to evaluate its KAT6 inhibitor OP-3136, in combination with Bayer’s NUBEQA (darolutamide), for metastatic castration-resistant prostate cancer (mCRPC). The Phase 1b/2 study will enroll approximately 36 patients, assessing safety, tolerability, and preliminary anti-tumor activity, with initiation expected in the second half of 2026. Olema maintains full global commercial rights to OP-3136, while clinical data and inventions related to the combined use will be jointly owned.
Olema Oncology Announces Clinical Trial Collaboration and
Olema Oncology has announced a clinical trial collaboration and supply agreement with Bayer AG to evaluate OP-3136, a KAT6 inhibitor, in combination with NUBEQA® (darolutamide) for metastatic castration-resistant prostate cancer (mCRPC). The Phase 1b/2 study will assess the safety, tolerability, and anti-tumor activity in approximately 36 patients, with initiation expected in the second half of 2026. This collaboration marks the first clinical partnership for OP-3136, aiming to expand treatment options for patients with this aggressive disease.
Olema Oncology (NASDAQ: OLMA) inks Bayer trial deal for OP-3136 combo
Olema Pharmaceuticals has entered a clinical trial collaboration and supply agreement with Bayer to evaluate its novel KAT6 inhibitor OP-3136 in combination with Bayer's NUBEQA (darolutamide) for metastatic castration-resistant prostate cancer. The planned Phase 1b/2 study, expected to start in the second half of 2026, will assess safety, tolerability, and preliminary anti-tumor activity in approximately 36 patients. Olema will lead the trial and retain global commercial rights to OP-3136, with joint ownership of data and inventions.
Olema Pharmaceuticals (OLMA) Is Up 6.0% After Encouraging Early OP-3136 Data - Has The Bull Case Changed?
Olema Pharmaceuticals reported encouraging preliminary Phase 1 data for its oral KAT6 inhibitor, OP-3136, showing good tolerability and early anti-tumor activity. While the company faces financial risks with rising net losses and ongoing cash burn, the success of OP-3136 strengthens Olema’s long-term investment narrative beyond its primary asset, palazestrant. The stock's future performance hinges on continued positive clinical execution and potential partnerships.
Olema Oncology Sees Early Hope As Cancer Drug Shows Tumor Shrinkage In Phase 1 Study
Olema Oncology's experimental cancer drug, OP-3136, showed promising results in a Phase 1 clinical study, with nearly two-thirds of evaluable patients experiencing tumor shrinkage across various cancer types. The drug, a KAT6 inhibitor, demonstrated a clean safety profile with mild to moderate side effects and no dose-limiting toxicities. These early findings support its continued development, particularly in combination with palazestrant for metastatic breast cancer, and the data will be presented at the ASCO Annual Meeting.
H.C. Wainwright reiterates Olema Pharmaceuticals stock rating at buy
H.C. Wainwright maintained a Buy rating and $38.00 price target for Olema Pharmaceuticals (NASDAQ:OLMA) following the release of ASCO abstracts. The company announced positive Phase 1 data for its KAT6 inhibitor, OP-3136, in advanced breast cancer, showing tumor shrinkage in a significant number of evaluable patients. This comes amidst other recent positive developments including Guggenheim's adjusted price target, Jefferies initiating Buy coverage, and a new director appointment.
